Cargando…

Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1(-) stem cell-like T cells over PD-1(+) T cells curbing tumor progression

INTRODUCTION: A high frequency of mutations affecting the gene encoding Herpes Virus Entry Mediator (HVEM, TNFRSF14) is a common clinical finding in a wide variety of human tumors, including those of hematological origin. METHODS: We have addressed how HVEM expression on A20 leukemia cells influence...

Descripción completa

Detalles Bibliográficos
Autores principales:	del Rio, Maria-Luisa, de Juan, Carla Yago-Diez, Roncador, Giovanna, Caleiras, Eduardo, Álvarez-Esteban, Ramón, Pérez-Simón, José Antonio, Rodriguez-Barbosa, Jose-Ignacio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076739/ https://www.ncbi.nlm.nih.gov/pubmed/37033927 http://dx.doi.org/10.3389/fimmu.2023.1113858

Ejemplares similares

Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance
por: del Rio, Maria-Luisa, et al.
Publicado: (2022)

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
por: Cantero-Cid, Ramón, et al.
Publicado: (2018)

PD-L1 is preferentially expressed on CD44+ tumor-initiating cells in head and neck squamous cell carcinoma
por: Lee, Yunqin, et al.
Publicado: (2014)

Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors
por: Curnock, Adam P., et al.
Publicado: (2021)

Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
por: Arrieta, Oscar, et al.
Publicado: (2017)

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
por: Zhao, Yunlong, et al.
Publicado: (2018)

Cancer stem cell-derived extracellular vesicles preferentially target MHC-II–macrophages and PD1+ T cells in the tumor microenvironment
por: Gonzalez-Callejo, Patricia, et al.
Publicado: (2023)

HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma
por: Malissen, Nausicaa, et al.
Publicado: (2019)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
por: Kammerer-Jacquet, Solène-Florence, et al.
Publicado: (2019)

Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
por: Chu, Fuliang, et al.
Publicado: (2014)

PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
por: Pico de Coaña, Yago, et al.
Publicado: (2020)

LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer
por: Shen, Dan-Dan, et al.
Publicado: (2022)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

Regulatory Effect of PD1/PD-Ligand 1 (PD-L1) on Treg Cells in Patients with Idiopathic Pulmonary Fibrosis
por: Wang, Bing, et al.
Publicado: (2021)

Synovial T cell hyporesponsiveness to myeloid dendritic cells is reversed by preventing PD-1/PD-L1 interactions
por: Moret, Frederique M, et al.
Publicado: (2014)

PD-L1/PD-L2-expressing B-1 cells inhibit alloreactive T cells in mice
por: Hirose, Takayuki, et al.
Publicado: (2017)

PD-1/PD-L1 signaling in JIA synovial regulatory T cell function
por: de Roock, Sytze, et al.
Publicado: (2011)

PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Aung, Phyu P., et al.
Publicado: (2019)

PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
por: Kamada, Takahiro, et al.
Publicado: (2019)

Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups
por: Tomassen, T., et al.
Publicado: (2022)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
por: Spirina, Liudmila, et al.
Publicado: (2021)

Increase of cells expressing PD‐1 and PD‐L1 and enhancement of IFN‐γ production via PD‐1/PD‐L1 blockade in bovine mycoplasmosis
por: Goto, Shinya, et al.
Publicado: (2017)

Nectin-1 and HVEM: cellular receptors for HSV-1 in skin
por: Knebel-Mörsdorf, Dagmar
Publicado: (2016)

Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer
por: Li, Yaqi, et al.
Publicado: (2016)

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
por: Sun, Yuxin, et al.
Publicado: (2020)

Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1
por: Makowska, Anna, et al.
Publicado: (2020)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
por: Pesce, Silvia, et al.
Publicado: (2019)

ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma
por: Huang, Hua, et al.
Publicado: (2021)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

HVEM Signalling Promotes Colitis
por: Schaer, Corinne, et al.
Publicado: (2011)

PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment
por: Hassan, Syeda S., et al.
Publicado: (2015)

Conditional Deletion of Pdcd1 Identifies the Cell-Intrinsic Action of PD-1 on Functional CD8 T Cell Subsets for Antitumor Efficacy
por: Raghavan, Sukanya, et al.
Publicado: (2021)

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006)

PD1/PD-L1 dependent immunosuppression by huiPS-derived cell population
por: Pini, Jonathan, et al.
Publicado: (2011)

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
por: Shi, Li, et al.
Publicado: (2013)

Enhancement of T cell immunity to osteosarcoma through modulation of PD-1/PD-L1 interactions
por: Lussier, Danielle M, et al.
Publicado: (2013)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mrbrfk9jv4levk12h56a5ipm1k